Brukinsa (zanubrutinib) / Medison, BeiGene  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brukinsa (zanubrutinib) / BeiGene
2020-000547-31: An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the lymph nodes

Not yet recruiting
3
700
Europe
Zanubrutinib, BGB-3111, Capsule
BeiGene, Ltd., BeiGene Ltd., BeiGene, Ltd.,
B-cell malignancies, blood cancer in the lymph nodes, Diseases [C] - Cancer [C04]
 
 
SEQUOIA, NCT03336333 / 2017-001551-31: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Checkmark Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Jul 2021 - Jul 2021: Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Checkmark Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Active, not recruiting
3
590
Europe, US, RoW
Zanubrutinib, BGB-3111, BRUKINSA, Bendamustine, Treanda, Ribomustin, and Levact, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta, Venclyxto
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/21
09/26
ASPEN, NCT03053440 / 2016-002980-33: A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

Hourglass Dec 2023 - Dec 2023 : Data from ASPEN trial for Waldenstrom macroglobulinemia at ASH 2023
Checkmark In combination with Imbruvica for ASPEN trial
Jun 2021 - Jun 2021: In combination with Imbruvica for ASPEN trial
Checkmark Data in WM
May 2019 - May 2019: Data in WM
More
Completed
3
201
Europe, US, RoW
BGB-3111, Zanubrutinib, Brukinsa, Ibrutinib, IMBRUVICA
BeiGene
Waldenström's Macroglobulinemia
06/22
06/22
ALPINE, NCT03734016 / 2018-001366-42: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Checkmark Data from ALPINE trial for CLL at ASH 2022
Dec 2022 - Dec 2022: Data from ALPINE trial for CLL at ASH 2022
Completed
3
652
Europe
Zanubrutinib, BGB-3111, Brukinsa, Ibrutinib, Imbruvica
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/22
02/24
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
BGB-3111-306, NCT04002297 / 2019-000413-36: Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Active, not recruiting
3
510
Japan
zanubrutinib, BGB-3111, Brukinsa, bendamustine, rituximab
BeiGene
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
03/27
12/27
BGB-3111-LTE1, NCT04170283: Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

Recruiting
3
500
Europe, US, RoW
Zanubrutinib, BGB-3111, Tislelizumab, BGB-A317
BeiGene
B-cell Malignancies
11/27
12/28
MAHOGANY, NCT05100862: A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting
3
750
Europe, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Rituximab, Rituxan, MabThera, Ruxience, Truxima, Lenalidomide, Revlimid, Obinutuzumab
BeiGene
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
07/28
06/30
CELESTIAL-TNCLL, NCT06073821: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
640
Europe, Canada, US, RoW
Sonrotoclax, BGB-11417, Zanubrutinib, BGB-3111, Venetoclax, Obinutuzumab
BeiGene
CLL
02/32
12/32
NCT05707377: A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Recruiting
2/3
282
Europe, US, RoW
Zanubrutinib, BGB-3111, Tacrolimus
BeiGene
Primary Membranous Nephropathy
12/28
12/28

Download Options